SCHEMBL6056936

SCHEMBL6056936

COc1nc(-c2ccccc2)cnc1CCl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDCD1 Q15116 9/20 0.48
CD274 Q9NZQ7 9/20 0.48
MAPT P10636 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
ALDH1A1 P00352 1/20 0.48
GLA P06280 1/20 0.48
GAA P10253 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
SQOR Q9Y6N5 3/20 0.46
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.41
TSHR P16473 1/20 0.41
ATM Q13315 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
PDGFRB P09619 1/20 0.41
KDR P35968 1/20 0.41
FLT3 P36888 1/20 0.41
IDO1 P14902 1/20 0.40
TDO2 P48775 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6056998 0.86 SQOR (0.51) PDCD1CD274MAPTSMN1; SMN2ALDH1A1
SCHEMBL29131667 0.80 SQOR (0.59) MAPTSMN1; SMN2ALDH1A1GLAGAA
SCHEMBL30505741 0.80 SQOR (0.59) MAPTSMN1; SMN2ALDH1A1GLAGAA
SCHEMBL2581392 0.76 MAPT (0.51) MAPTSMN1; SMN2ALDH1A1GLAGAA
SCHEMBL6056985 0.73 PDCD1 (0.38) PDCD1CD274MAPTKMT2AMEN1
SCHEMBL7545059 0.70 IKBKB (0.55) MAPTSMN1; SMN2ALDH1A1GLAGAA
SCHEMBL6057019 0.70 PDCD1 (0.48) PDCD1CD274MAPTSMN1; SMN2ALDH1A1
SCHEMBL16622256 0.70 SQOR (0.51) PDCD1CD274MAPTSMN1; SMN2ALDH1A1
SCHEMBL6356399 0.69 NPC1 (0.47) MAPTSMN1; SMN2ALDH1A1GLAGAA
SCHEMBL7542109 0.69 MAPT (0.44) MAPTSMN1; SMN2ALDH1A1GLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6982268-B2 Substituted imidazolylmethyl pyridine and pyrazine derivatives GABAA receptor ligands NEUROGEN CORPORATION (US) 2006-01-03 US disclosed
EP-1501825-A2 SUBSTITUTED IMIDAZOLYLMETHYL PYRIDINE AND PYRAZINE DERIVATIVES: GABA A RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 2005-02-02 EP disclosed
WO-2004041809-A2 SUBSTITUTED IMIDAZOLYLMETHYL PYRIDINE AND PYRAZINE DERIVATIVES AND THEIR USE AS GABAA RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 2004-05-21 WO disclosed
US-20030220348-A1 Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands NEUROGEN CORPORATION 2003-11-27 US disclosed
US-20030220348-A1 Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands NEUROGEN CORPORATION 2003-11-27 US disclosed
US-20030220348-A1 Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands NEUROGEN CORPORATION 2003-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220348-A1 Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands GABRP, GABBR1, GABRA1 PDCD1 810/4885CD274 972/4885MAPT 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.